Suppr超能文献

糖尿病和其他基础疾病与 2019 冠状病毒病相关的鼻-眶-脑毛霉菌病:系统评价和荟萃分析。

Diabetes mellitus and other underlying conditions in patients with coronavirus disease 2019 associated rhino-orbito-cerebral mucormycosis: a systematic review and meta-analysis.

机构信息

Department of Otolaryngology, Kurdistan University of Medical Sciences, Sanandaj, Iran.

Department of Otorhinolaryngology and Head & Neck Surgery, Amir-Alam Hospital, Tehran University of Medical Sciences, Tehran, Iran.

出版信息

J Laryngol Otol. 2022 Sep;136(9):788-798. doi: 10.1017/S0022215122001074. Epub 2022 May 6.

Abstract

OBJECTIVE

This study aimed to compute the pooled prevalence of diabetes mellitus and other underlying conditions in patients with coronavirus disease 2019 associated rhino-orbito-cerebral mucormycosis.

METHOD

A systematic literature review was performed in PubMed, Scopus, Web of Science, Embase and Google Scholar. The cross-sectional studies that reported the frequency of diabetes mellitus in patients with coronavirus disease 2019 associated rhino-orbito-cerebral mucormycosis were included.

RESULTS

Eighteen eligible studies with a total number of 3718 patients were included in the current study. The pooled prevalence of diabetes in patients with coronavirus disease 2019 associated rhino-orbito-cerebral mucormycosis was 89 per cent and with new-onset diabetes was 32 per cent. The pooled prevalence of steroid use was high (79 per cent) too. The all-cause mortality rate was 24 per cent.

CONCLUSION

Diabetes mellitus was the most frequent underlying condition in patients with coronavirus disease 2019 associated rhino-orbito-cerebral mucormycosis. The second most frequent underlying condition was steroid use during coronavirus disease 2019 infection. The appropriate control of hyperglycaemia and rational prescription of steroids during the treatment of coronavirus disease 2019 associated rhino-orbito-cerebral mucormycosis is recommended.

摘要

目的

本研究旨在计算与 2019 年冠状病毒病相关的鼻-眶-脑毛霉菌病患者中糖尿病和其他潜在疾病的汇总患病率。

方法

在 PubMed、Scopus、Web of Science、Embase 和 Google Scholar 中进行了系统的文献回顾。纳入了报告与 2019 年冠状病毒病相关的鼻-眶-脑毛霉菌病患者中糖尿病患病率的横断面研究。

结果

本研究共纳入 18 项符合条件的研究,共计 3718 例患者。与 2019 年冠状病毒病相关的鼻-眶-脑毛霉菌病患者中糖尿病的汇总患病率为 89%,新发糖尿病患病率为 32%。皮质类固醇的使用患病率也很高(79%)。全因死亡率为 24%。

结论

糖尿病是与 2019 年冠状病毒病相关的鼻-眶-脑毛霉菌病患者中最常见的潜在疾病。皮质类固醇的使用在 2019 年冠状病毒病感染期间是第二常见的潜在疾病。建议在治疗与 2019 年冠状病毒病相关的鼻-眶-脑毛霉菌病时,适当控制高血糖和合理使用皮质类固醇。

相似文献

2
Clinical Features and Mortality of COVID-19-Associated Mucormycosis: A Systematic Review and Meta-Analysis.
Mycopathologia. 2022 Jun;187(2-3):271-289. doi: 10.1007/s11046-022-00627-8. Epub 2022 Mar 21.
3
Outcomes of surgical management in orbital cellulitis due to mucormycosis in patients recovered from COVID-19.
Indian J Ophthalmol. 2025 Jun 1;73(Suppl 3):S472-S477. doi: 10.4103/IJO.IJO_1567_24. Epub 2025 May 30.
4
Gastrointestinal mucormycosis: A periodic systematic review of case reports from 2015 to 2021.
Microb Pathog. 2022 Feb;163:105388. doi: 10.1016/j.micpath.2022.105388. Epub 2022 Jan 4.
5
Epidemiology and Pathophysiology of COVID-19-Associated Mucormycosis: India Versus the Rest of the World.
Mycopathologia. 2021 Dec;186(6):739-754. doi: 10.1007/s11046-021-00584-8. Epub 2021 Aug 19.
6
Mucormycosis following burn injuries: A systematic review.
Burns. 2023 Feb;49(1):15-25. doi: 10.1016/j.burns.2022.05.012. Epub 2022 May 13.
8
Coincidence or reality behind Mucormycosis, diabetes mellitus and Covid-19 association: A systematic review.
J Mycol Med. 2022 Aug;32(3):101257. doi: 10.1016/j.mycmed.2022.101257. Epub 2022 Feb 18.
10
Antibody tests for identification of current and past infection with SARS-CoV-2.
Cochrane Database Syst Rev. 2022 Nov 17;11(11):CD013652. doi: 10.1002/14651858.CD013652.pub2.

引用本文的文献

2
Risk Factors of COVID-19 associated mucormycosis in Iranian patients: a multicenter study.
BMC Infect Dis. 2024 Aug 22;24(1):852. doi: 10.1186/s12879-024-09755-6.
3
Exploring Prevalence Trends of Jaw Bone Pathologies: A Three-Year Institutional Study.
Cureus. 2024 May 18;16(5):e60574. doi: 10.7759/cureus.60574. eCollection 2024 May.

本文引用的文献

3
Role of COVID 19 Inflammatory Markers in Rhino-Orbito-Cerebral Mucormycosis: A Case Study in Predisposed Patients at a Designated Nodal Centre.
Indian J Otolaryngol Head Neck Surg. 2022 Oct;74(Suppl 2):3498-3504. doi: 10.1007/s12070-021-02970-6. Epub 2021 Nov 13.
4
5
Rhino-orbito-cerebral Mucormycosis: Pictorial Review.
Insights Imaging. 2021 Nov 12;12(1):167. doi: 10.1186/s13244-021-01109-z.
6
Management Challenge of Rhino-Orbito-Cerebral Mucormycosis in Covid 19 Era: A Prospective Observational Study.
Indian J Otolaryngol Head Neck Surg. 2022 Oct;74(Suppl 2):3485-3491. doi: 10.1007/s12070-021-02947-5. Epub 2021 Oct 23.
8
COVID-19-Associated Mucormycosis (CAM): An Updated Evidence Mapping.
Int J Environ Res Public Health. 2021 Sep 30;18(19):10340. doi: 10.3390/ijerph181910340.
9
New-onset diabetes in COVID-19 and clinical outcomes: A systematic review and meta-analysis.
World J Virol. 2021 Sep 25;10(5):275-287. doi: 10.5501/wjv.v10.i5.275.
10
Predisposing factors of rhino-orbital-cerebral mucormycosis in patients with COVID 19 infection.
Indian J Otolaryngol Head Neck Surg. 2022 Oct;74(Suppl 2):3151-3157. doi: 10.1007/s12070-021-02875-4. Epub 2021 Sep 25.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验